Egetis Therapeutics to Host Virtual KOL Event to Discuss MCT8 Deficiency and Emcitate® (tiratricol) on March 4, 2025

Stockholm, Sweden, February 25, 2025. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced that it will host a virtual key opinion leader (KOL) event for analysts and investors on Tuesday March 4, 2025, at 2.45-3.30 pm (CET) / 8.45-9.30 am (EST), featuring Professor Edward Visser, Erasmus University Medical Center, Rotterdam, The Netherlands. Professor Visser will discuss the medical need in MCT8 deficiency and published data on Emcitate® (tiratricol) in treating patients with MCT8 deficiency. Egetis gained marketing authorisation for Emcitate for MCT8 deficiency by the EU Commission on February 13, 2025.

If you wish to participate via webcast please use the link below. Via the webcast you can ask written questions.
https://egetis.events.inderes.com/kol-event-2025

If you wish to participate via teleconference please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/egetis/kol-event-2025/dial-in

The KOL event will be made available on the Company’s website after the call.

Datum 2025-02-25, kl 11:00
Källa MFN
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet